Investigational Drug Information for LB-102
✉ Email this page to a colleague
What is the drug development status for LB-102?
LB-102 is an investigational drug.
There have been 3 clinical trials for LB-102.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 4th 2023.
The most common disease conditions in clinical trials are Schizophrenia and [disabled in preview]. The leading clinical trial sponsors are LB Pharmaceuticals Inc., Washington University School of Medicine, and [disabled in preview].
Summary for LB-102
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2023-12-04) |
| Vendors | 0 |
Recent Clinical Trials for LB-102
| Title | Sponsor | Phase |
|---|---|---|
| Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia | LB Pharmaceuticals Inc. | Phase 2 |
| Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers | Washington University School of Medicine | Phase 1 |
| Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers | LB Pharmaceuticals Inc. | Phase 1 |
Clinical Trial Summary for LB-102
Top disease conditions for LB-102
Top clinical trial sponsors for LB-102
US Patents for LB-102
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
